Prosight Management, LP
Prosight Management, LP reported 36 holdings worth US$580M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Prosight Management, LP reported 36 holdings worth US$580M as of Jun 30, 2026. Largest: Lakefront Biotherapeutics, Janux Therapeutics, Inc. and Nektar Therapeutics. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 36
- Value as reported
- US$580M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Lakefront Biotherapeutics | 2.04M | US$61.3M | 10.6% |
| Janux Therapeutics, Inc. | 3.8M | US$58.4M | 10.1% |
| Nektar Therapeutics | 810K | US$56.5M | 9.7% |
| Boston Scientific Corporation | 1.27M | US$54.2M | 9.3% |
| Shattuck Labs, Inc. | 5.96M | US$41.3M | 7.1% |
| Insmed Incorporated | 376K | US$40M | 6.9% |
| Alnylam Pharmaceuticals, Inc. | 98,080 | US$29.5M | 5.1% |
| Syndax Pharmaceuticals, Inc. | 1.2M | US$26.2M | 4.5% |
| Kura Oncology, Inc. | 2.02M | US$22.2M | 3.8% |
| Irhythm Holdings, Inc. | 166K | US$19.7M | 3.4% |
| Veeva Systems Inc. | 106K | US$18.8M | 3.2% |
| Zymeworks Inc. | 674K | US$17.6M | 3.0% |
| Abivax Sa | 107K | US$14.3M | 2.5% |
| Crinetics Pharmaceuticals, Inc. | 375K | US$14M | 2.4% |
| Mineralys Therapeutics, Inc. | 450K | US$12.1M | 2.1% |
| Icu Medical, Inc. | 51,000 | US$7.48M | 1.3% |
| Intuitive Surgical, Inc. | 17,000 | US$6.76M | 1.2% |
| Corbus Pharmaceuticals Holdings, Inc. | 650K | US$6.1M | 1.1% |
| Procept Biorobotics Corporation | 268K | US$6.06M | 1.0% |
| Genedx Holdings Corp. | 85,500 | US$5.87M | 1.0% |
| Option Care Health, Inc. | 271K | US$5.68M | 0.98% |
| Onkure Therapeutics, Inc. | 979K | US$4.46M | 0.77% |
| Emergent Biosolutions Inc. | 460K | US$3.85M | 0.66% |
| Pfizer, Inc. | 135K | US$3.26M | 0.56% |
| Orthopediatrics Corp. | 158K | US$3.01M | 0.52% |
| Rocket Pharmaceuticals, Inc. | 700K | US$2.39M | 0.41% |
| An2 Therapeutics, Inc. | 475K | US$2.3M | 0.40% |
| Pliant Therapeutics, Inc. | 1.37M | US$1.56M | 0.27% |
| Tectonic Therapeutic, Inc. | 39,731 | US$1.37M | 0.24% |
| Meiragtx Holdings Plc | 90,000 | US$1.22M | 0.21% |
| Everforth, Inc. | 67,500 | US$1.21M | 0.21% |
| Rein Therapeutics, Inc. | 1.1M | US$1.14M | 0.20% |
| Coya Therapeutics, Inc. | 170K | US$995K | 0.17% |
| Immuneering Corporation | 36,861 | US$184K | 0.03% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Transmedics Group, Inc. | 0 | US$0 | 0.00% |
| Trueblue, Inc. | 0 | US$0 | 0.00% |
| Upstream Bio, Inc. | 0 | US$0 | 0.00% |
| Viking Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Adicet Bio, Inc. | 0 | US$0 | 0.00% |
| Concentra Group Holdings Parent, Inc. | 0 | US$0 | 0.00% |
| Immunovant, Inc. | 0 | US$0 | 0.00% |
| Omeros Corporation | 0 | US$0 | 0.00% |
| Palvella Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Phreesia, Inc. | 0 | US$0 | 0.00% |
| Regenxbio Inc. | 0 | US$0 | 0.00% |
| Roivant Sciences Ltd. | 0 | US$0 | 0.00% |
| Schrodinger, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related